Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 1, 2000, Pages 50-54

  Platzer, Peter ^a   Thalhammer, Theresia ^a   Hamilton, Gerhard ^b   Ulsperger, Ernst ^b   Rosenberg, Erwin ^c   Wissiack, Rene ^c   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Anticancer drugs; Camptothecin; Metabolism; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DRUG METABOLITE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG BILE LEVEL; DRUG METABOLISM; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033976227     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006742     Document Type: Article

References (20)

1. 1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim, GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888
2. 2. Pantazis P (1995) Preclinical studies of water-insoluble camp-tothecin congeners: cytotoxicity, development of resistance, and combination treatment. Clin Cancer Res 1: 1235
3. 3. Ling Y-H, Perez-Soler R, Tseng MT (1993) Effect of DNA topoisomerase I inhibitor, 10-hydroxycamptothecin, on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells. Anticancer Res 13: 1613
4. 4. Liu LF (1995) Biochemistry of camptothecin. In: Potmesil M, Pinedo H (eds) Camptothecins: new anticancer agents. CRC Press, Boca Raton, p 9
5. 5. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046
6. 6. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER, Giovanella BC (1993) Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 5: 273
7. 7. Pantazis P, Kozielski AJ, Rodriguez R, Petry E, Wall M, Giovanella BC (1994) Therapeutic efficacy of camptothecin-derivatives against human malignant melanoma xenografts. Melanoma Res 4: 5
8. 8. Gottlieb JA, Guarino AM, Call JB, Block JB (1970) Preliminary pharmacological and clinical evaluation of camptothecin sodium (NCS 100880). Cancer Chemother Rep 54: 461
9. 9. Muggia FM, Creaven PT, Hansen HH, Cohen MN, Selawny DS (1972) Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies. Cancer Chemother Rep 56: 515
10. 10. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465
11. 11. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res 51: 3052
12. 12. Potmesil M, Giovanella BC (1995) Preclinical development of 20(S)-camptothecin, 9-aminocamptothecin, and other analogues. In: Potmesil M, Pinedo H (eds) Camptothecins: new anticancer agents. CRC Press, Boca Raton, p 41
13. 13. Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC (1995) Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 55: 5637
14. 14. Stehlin JS, Natelson EA, Hinz HR, Giovanella BC, Ipolyi PD de, Fehir KM, Trezona TP, Vardeman DM, Harris NJ, Marcee AK, Kozielski AJ, Ruiz-Razura A (1995) Phase I clinical trial and pharmacokinetics results with oral administration of 20(S)-camptothecin. In: Potmesil M, Pinedo H (eds) Camptothecins: new anticancer agents. CRC Press, Boca Raton, p 59
15. 15. Gupta E, Sinko P, Saleem A, Li XG, Zamek R, Goodin S, Toppmeyer D, Nathelson E, Giovanella B, Rubin E (1997) Oral multiple-dose camptothecin (CPT) pharmacokinetics: evidence of inter-patient variability. Proc Am Assoc Cancer Res 38: 75
16. 16. Toppmeyer D, Gupta E, Saleem A, Zamek R, Much J, Ibrahim N, Bindi M, Haluska P, Li XG, Goodin S, Aisner J, Natelson E, Giovanella B (1997) A phase I pharmacokinetic and pharmacodynamic study of camptothecin (CPT) and etoposide (E) in patients with advanced malignancies. Proc Am Soc Clin Oncol 16: 203a
17. 17. Thalhammer T, Stapf V, Gajdzik L, Graf J (1994) Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport. Eur J Pharmacol 270: 213
18. 18. Sallustio BC, Fairchild BA, Shanahan K, Evans AM, Nation RL (1996) Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab Dispos 42: 984
19. 19. Lokiec F, Monegier du Sorbier B, Sanderink G-J (1996) Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 2: 1943
20. 20. Zhang R, Li Y, Cai Q, Liu T, Sun H, Chambless B (1998) Preclinical pharmacology of the natural product anticancer agent 10-hydroxy-camptothecin, an inhibitor of topoisomerase I. Cancer Chemother Pharmacol 41: 257